Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[11C]CPPC PET Imaging in Long COVID
NCT06223971Phase 1Completed
- Sponsor
- Johns Hopkins University
- Start
- Aug 2024
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of 11C-CPPC in post-COVID-19 condition (PCC) (2 arms), sponsored by Johns Hopkins University. Primary endpoints: Safety and tolerability of [11C]CPPC at 2 days, Change in complete blood count (CBC) test at 2 days and 1 more. Started Aug 2024; status: completed.
02
Drugs
11C-CPPC
03
Conditions
post-COVID-19 condition (PCC)
Beyond the preview
Go deeper on NCT06223971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06223971.